Torsten Falk

Biography

Dr. Falk is a Professor of Neurology and of Pharmacology, and he is the Director of the Preclinical Parkinson's disease Laboratory.  He has received his PhD from the University of Hamburg, Germany.  Dr. Falk is the author of over 45 peer-reviewed journal publications, with an h-index of 24, an I-10-index  of 35, and over 160 peer-reviewed abstracts and conference presentations. He holds two patents and his work has led to ongoing Clinical trials testing a novel treatment for levodopa-induced dyskinesias. He is also Co-founder and equity partner in Teleport Pharmaceuticals, LLC. He is a standing member of the NIH Clinical Neurotransmitters and Neuroplasticity (CNNT) study section. He is an ad hoc reviewer for the Michael J. Fox Foundation for Parkinson's Research, as well as the Cure Parkinson's and Parkinson’s UK Foundations. He has been a Member of the Grant Review Committee for the Parkinson's Foundation (PF).  

Degrees

• Ph.D. Neurobiology
• Institute for Cellular Biochemistry and Clinical Neurobiology, UKE, University of Hamburg, Hamburg, Hamburg, Germany
• Cloning, mRNA distribution and functional characterization of an inwardly rectifying potassium channel
• M.S. Genetics
• Department of Genetics, University of Kaiserslautern, Kaiserslautern, Rhineland-Palatinate, Germany
• Generation of a temperature sensitive plasmid replication mutant of the Streptomyces plasmid SCP 2*

Awards

• Basic and Translational Investigator Award
• UA COM-T Faculty Excellence Award, Spring 2023
• Travel Stipend 39th Blankenese Conference; Signaling in Health and Disease
• Center for Molecular Neurobiology Hamburg (ZMNH), Germany, Spring 2019
• Travel Stipend 35th Blankenese Conference; Brain Repair: From Regeneration to Cellular Reprogramming
• Center for Molecular Neurobiology Hamburg (ZMNH), Germany, Spring 2015